💉 Does bimekizumab work in real-world PsA? YES - EuroSpA: 76% retention at 6months 46% DAPSA LDA in 787pts across 12 registries #OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB

• https://x.com/Nellziade/status/2062543554623291769/photo/1

🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA? YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts #OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN

• https://x.com/Nellziade/status/2062542859106910588/photo/1

🧬 Do biomarkers predict #zasocitinib response in PsA? YES: TYK2/IL-17 pathway markers predict ACR20 in 290pts Phase 2b RCT #OP0184 #EULAR2026 @RheumNow https://t.co/AVlyrauI5q

• https://x.com/Nellziade/status/2062542434538602642/photo/1

Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810

After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow

💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr? Phase2b/3 RCT: ~50% ACR50 at week in 343pts OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c

• https://x.com/Nellziade/status/2062265661829611550/photo/1

Roc-SpA study Active axSpA dse + inad response to TNFi ➡️switch or cycled No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi Shared decision is key AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv

• https://x.com/RHEUMarampa/status/2062438779202261286/photo/1

Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+

It's unclear whether GLP-1agonists inmpvove PsA from weight loss or other MoA 74 PsA patients on GLP-1RA vs 74 matched controls (BMI + disease activity matched) After adjusting for BMI change PROs still improve cDAPSA (-0.4/mo) DAPSA (-0.6/mo) and pain but not SJC, TJC or CRP https://t.co/dcaU2jwbKJ

• https://x.com/AurelieRheumo/status/2062218873886384253/photo/1

Izokibep IL-17A Affibody PsA 343 pts RCT PBO crossover wk16 52 wks data ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52% No diff between QW vs Q2W AE Injection-site reactions, URTIs most common No new safety signals Looks like any other IL17Ai to me #EULAR2026 #OP073 https://t.co/WiHT8Plitn

• https://x.com/AurelieRheumo/status/2062215108231663736/photo/1

Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY

• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1

At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu

• https://x.com/synovialjoints/status/2062211485212832125/photo/1

Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886

• https://x.com/synovialjoints/status/2062210281942417906/photo/1

In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

• https://x.com/synovialjoints/status/2062208390512660905/photo/1

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6

• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1
• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1
• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1